Year archive

Can-Fite BioPharma Ltd. — 2024 filings

All 140 regulatory filings released by Can-Fite BioPharma Ltd. (CANF) in 2024, sourced directly from the official regulator.

140 Filings

2024 Period

2024 filings (140)

Filing	Released	Lang
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-12-30	English
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson Regulatory Filings	2024-12-30	English
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson Report Publication Announcement	2024-12-30	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-12-04	English
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug Regulatory Filings	2024-12-04	English
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug Report Publication Announcement	2024-12-04	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-11-14	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-11-12	English
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial Regulatory Filings	2024-11-11	English
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial Regulatory Filings	2024-11-11	English
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia Regulatory Filings	2024-11-04	English
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia Report Publication Announcement	2024-11-04	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-11-04	English
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson Regulatory Filings	2024-10-18	English
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson Report Publication Announcement	2024-10-18	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-10-18	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-10-09	English
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer Regulatory Filings	2024-10-09	English
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer Regulatory Filings	2024-10-09	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-09-24	English
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis Regulatory Filings	2024-09-24	English
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis Report Publication Announcement	2024-09-24	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-09-16	English
Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health Regulatory Filings	2024-09-16	English
Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health Report Publication Announcement	2024-09-16	English
Regulatory Filings 2024 Regulatory Filings	2024-09-09	English
PROSPECTUS Regulatory Filings	2024-09-06	English
PROSPECTUS - up to an aggregate of up to 1,774,285,800 ordinary share issuable upon the exercise of warrants, Capital/Financing Update	2024-09-06	English
PROSPECTUS - up to an aggregate of up to 1,774,285,800 ordinary share issuable upon the exercise of warrants, Regulatory Filings	2024-09-06	English
Regulatory Filings 2024 Regulatory Filings	2024-09-06	English
Regulatory Filings 2024 Regulatory Filings	2024-09-06	English
Regulatory Filings 2024 Regulatory Filings	2024-09-05	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-08-30	English
REGISTRATION STATEMENT Regulatory Filings	2024-08-30	English
Adoption of an ATM plan Regulatory Filings	2024-08-30	English
Adoption of an ATM plan Report Publication Announcement	2024-08-30	English
POST-EFFECTIVE AMENDMENT NO. 7 TO FORM F-1 Regulatory Filings	2024-08-30	English
Resale Registration Statement on Form F-3 Capital/Financing Update	2024-08-30	English
Resale Registration Statement on Form F-3 Report Publication Announcement	2024-08-30	English
PROSPECTUS SUPPLEMENT Regulatory Filings	2024-08-30	English
Post Effective Amendment to Registration Statement-971,966,880 Ordinary Shares represented by 3,239,890 American Depositary Shares Capital/Financing Update	2024-08-30	English
Post Effective Amendment to Registration Statement-971,966,880 Ordinary Shares represented by 3,239,890 American Depositary Shares Report Publication Announcement	2024-08-30	English
Prospectus Supplement Registering ATM Shares Capital/Financing Update	2024-08-30	English
Prospectus Supplement Registering ATM Shares Report Publication Announcement	2024-08-30	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-08-29	English
financial results for the six months ended June 30, 2024 and updates on its drug development programs Interim / Quarterly Report H1 2024	2024-08-29	English
financial results for the six months ended June 30, 2024 and updates on its drug development programs Report Publication Announcement H1 2024	2024-08-29	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-08-12	English
FORM 6-K- Warrant Exercise sdocuments Regulatory Filings	2024-08-12	English
FORM 6-K- Warrant Exercise sdocuments Report Publication Announcement	2024-08-12	English
FORM 6-K-Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds Regulatory Filings	2024-08-09	English
FORM 6-K-Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds Regulatory Filings	2024-08-09	English
REPORT OF FOREIGN PRIVATE ISSUE Regulatory Filings	2024-08-09	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-07-29	English
FORM 6-K- Can-Fite Provides Namodenoson Patent Update Regulatory Filings	2024-07-29	English
FORM 6-K- Can-Fite Provides Namodenoson Patent Update Report Publication Announcement	2024-07-29	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-07-11	English
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer Regulatory Filings	2024-07-11	English
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer Report Publication Announcement	2024-07-11	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-07-03	English
Results of the Annual General Meeting of the Shareholders held on July 3, 2024 Regulatory Filings	2024-07-03	English
Results of the Annual General Meeting of the Shareholders held on July 3, 2024 AGM Information	2024-07-03	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-07-01	English
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson Regulatory Filings	2024-07-01	English
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson Report Publication Announcement	2024-07-01	English
PROSPECTUS SUPPLEMENT Regulatory Filings	2024-06-28	English
PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated January 5, 2024) Capital/Financing Update	2024-06-28	English
PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated January 5, 2024) Report Publication Announcement	2024-06-28	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-06-28	English
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix Regulatory Filings	2024-06-28	English
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix Report Publication Announcement	2024-06-28	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-06-26	English
Annual General Meeting will be reconvened on Wednesday, July 3, 2024 at 3:00p.m., Israel time AGM Information	2024-06-26	English
Annual General Meeting will be reconvened on Wednesday, July 3, 2024 at 3:00p.m., Israel time AGM Information	2024-06-26	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-06-24	English
Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver Regulatory Filings	2024-06-24	English
Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver Report Publication Announcement	2024-06-24	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-06-10	English
Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study Regulatory Filings	2024-06-10	English
Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study Report Publication Announcement	2024-06-10	English
Immediate Report of Meeting to be held on June 26, 2024- proxy-amendment AGM Information	2024-06-07	English
Immediate Report of Meeting to be held on June 26, 2024- proxy-amendment AGM Information	2024-06-07	English
Immediate Report of Meeting to be held on June 26, 2024- proxy-amendment Proxy Solicitation & Information Statement	2024-06-07	English
AMENDMENT NO. 1 TO FORM 6-K Regulatory Filings	2024-06-07	English
FORM 6-K Regulatory Filings	2024-06-05	English
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study Regulatory Filings	2024-06-05	English
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study Report Publication Announcement	2024-06-05	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-05-29	English
ndependent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases Regulatory Filings	2024-05-29	English
ndependent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases Report Publication Announcement	2024-05-29	English
2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON June 26, 2024 AGM Information	2024-05-22	English
2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON June 26, 2024 AGM Information	2024-05-22	English
2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON June 26, 2024 AGM Information	2024-05-22	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-05-22	English
75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study Regulatory Filings	2024-05-13	English
75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study Report Publication Announcement	2024-05-13	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-05-13	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-05-09	English
FDA grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study Regulatory Filings	2024-05-09	English
FDA grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study Report Publication Announcement	2024-05-09	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-05-06	English
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 Regulatory Filings	2024-05-06	English
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 Report Publication Announcement	2024-05-06	English
FORM 6-K Regulatory Filings	2024-04-25	English
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal Regulatory Filings	2024-04-25	English
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal Report Publication Announcement	2024-04-25	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-04-15	English
Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH Regulatory Filings	2024-04-15	English
Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH Report Publication Announcement	2024-04-15	English
Regulatory Filings 2024 Regulatory Filings	2024-04-10	English
REGISTRATION STATEMENT Regulatory Filings	2024-04-05	English
POST-EFFECTIVE AMENDMENT NO. 6 TO FORM F-1 Regulatory Filings	2024-04-05	English
FORM S-8-REGISTRATION STATEMENT Capital/Financing Update	2024-04-05	English
FORM S-8-REGISTRATION STATEMENT Report Publication Announcement	2024-04-05	English
Post Effective Amendment to Form F-1 Registration Statements Capital/Financing Update	2024-04-05	English
Post Effective Amendment to Form F-1 Registration Statements Regulatory Filings	2024-04-05	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-04-03	English
Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients Regulatory Filings	2024-04-03	English
Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients Report Publication Announcement	2024-04-03	English
20F FOR 2023 Annual Report FY 2023	2024-03-28	English
20F FOR 2023 Report Publication Announcement	2024-03-28	English
ANNUAL REPORT Annual Report FY 2023	2024-03-28	English
FORM 6-K- 2023 Financial Results and Clinical Update Earnings Release FY 2023	2024-03-28	English
FORM 6-K- 2023 Financial Results and Clinical Update Report Publication Announcement	2024-03-28	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-03-28	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-03-11	English
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference Regulatory Filings	2024-03-11	English
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference Report Publication Announcement	2024-03-11	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-02-28	English
Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada Regulatory Filings	2024-02-28	English
Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada Report Publication Announcement	2024-02-28	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-02-14	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-01-30	English
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication Regulatory Filings	2024-01-30	English
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication Report Publication Announcement	2024-01-30	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2024-01-29	English
Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study Regulatory Filings	2024-01-29	English
Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study Report Publication Announcement	2024-01-29	English
Regulatory Filings 2024 Regulatory Filings	2024-01-08	English
Regulatory Filings 2024 Regulatory Filings	2024-01-03	English

Filings by year

2026 72 filings
2025 144 filings
2024 140 filings
2023 170 filings
2022 110 filings
2021 151 filings
2020 315 filings
2019 251 filings
2018 150 filings
2017 166 filings
2016 178 filings
2015 160 filings
2014 129 filings
2013 34 filings
2012 2 filings